Search Results 471-480 of 10491 for Digoxin toxicity

  1. Patient Stories - Krista A. Goulding, M.D., M.P.H. - Mayo Clinic

    Search for a doctor. Krista A. Goulding, M.D., M.P.H.. Orthopedic Surgeon. Request an Appointment · Overview · News · Publications. Patient Stories.

  2. Lidocaine and tetracaine (topical application route) - Side effects & uses - Mayo Clinic

    Symptoms of overdose · Change in consciousness · fast, pounding, or irregular heartbeat or pulse · no blood pressure or pulse · stopping of the heart.

  3. Publications - Amit K. Ghosh, M.D., M.B.A. - Mayo Clinic

    Acute renal failure in a case of fatal chromic acid poisoning. Ren Fail ... Dig Dis Sci. 1993 Jul; 38(7):1347-50. View PubMed; Ghosh AK, Verma PP, Jha V ...

  4. Biperiden (oral route) - Side effects & dosage - Mayo Clinic

    Symptoms of overdose · Change in consciousness · chest pain or discomfort · convulsions · decreased awareness or responsiveness · decreased secretions of the mouth, ...

  5. Moxifloxacin (oral route) - Mayo Clinic

    Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, this medicine ...

  6. https://www.mayoclinic.org/arabic_organization_concepts.xml

  7. Trigeminal neuralgia - Doctors and departments - Mayo Clinic

    Learn about this nerve condition that can jolt areas on the face with electric-shock-like pain.

  8. Octreotide (injection route, intramuscular route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Get emergency help immediately if any of the following symptoms of overdose occur: Symptoms of overdose. Anxiety; blurred vision; chills; cold sweats; coma ...

  9. Liothyronine (intravenous route) - Side effects & dosage - Mayo Clinic

    Digoxin; Furosemide; Insulin Aspart, Recombinant; Insulin Glargine, Recombinant ... Symptoms of overdose. Cold clammy skin; increased bowel movements ...

  10. Ruxolitinib (oral route) - Mayo Clinic

    It is also used to treat chronic graft-versus-host disease (cGVHD) in patients who have been treated with 1 or 2 previous treatments that did not work well.